Amarantus Bioscience Holdings Inc
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprieta… Read more
Amarantus Bioscience Holdings Inc (AMBS) - Total Liabilities
Latest total liabilities as of March 2023: $34.92 Million USD
Based on the latest financial reports, Amarantus Bioscience Holdings Inc (AMBS) has total liabilities worth $34.92 Million USD as of March 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Amarantus Bioscience Holdings Inc - Total Liabilities Trend (2008–2022)
This chart illustrates how Amarantus Bioscience Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Amarantus Bioscience Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Amarantus Bioscience Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gold And Gemstone
PINK:GGSM
|
USA | $23.15K |
|
BARON OIL
BE:GHA
|
Germany | €204.00K |
|
U-Swirl Inc
PINK:SWRL
|
USA | $10.61 Million |
|
KYN Capital Group Inc
PINK:KYNC
|
USA | $1.75 Million |
|
Itokk Inc
PINK:IKTO
|
USA | $423.36K |
|
SPO Global Inc
PINK:SPOM
|
USA | $276.76K |
|
Sentry Technology Corp
PINK:SKVY
|
USA | $7.52 Million |
Liability Composition Analysis (2008–2022)
This chart breaks down Amarantus Bioscience Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amarantus Bioscience Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amarantus Bioscience Holdings Inc (2008–2022)
The table below shows the annual total liabilities of Amarantus Bioscience Holdings Inc from 2008 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $34.87 Million | +0.69% |
| 2021-12-31 | $34.63 Million | +0.80% |
| 2020-12-31 | $34.36 Million | +1.82% |
| 2019-12-31 | $33.74 Million | +7.50% |
| 2018-12-31 | $31.39 Million | +11.08% |
| 2017-12-31 | $28.26 Million | +5.77% |
| 2016-12-31 | $26.71 Million | +30.57% |
| 2015-12-31 | $20.46 Million | +223.26% |
| 2014-12-31 | $6.33 Million | -32.51% |
| 2013-12-31 | $9.38 Million | +97.94% |
| 2012-12-31 | $4.74 Million | +27.88% |
| 2011-12-31 | $3.70 Million | +4646.15% |
| 2010-12-31 | $78.06K | +285.54% |
| 2009-12-31 | $20.25K | +335.77% |
| 2008-12-31 | $4.65K | -- |